AusBiotech has launched the 2020 CEO Industry Position Survey, asking leaders of biotechnology companies for their views and policy priorities of our Australian life sciences sector.
This survey provides an independent perspective of the impact of the current economic and regulatory environment on the biotechnology industry. In its 10th year, CEOs of biotechnology and medtech companies are being asked to submit information regarding the financial environment, issues impacting their business, their current outlook, and their plans for the future. AusBiotech urges all recipients to participate.
The survey is conducted via mail and email during January and February, and is open to all ASX-listed and unlisted biotechnology and medtech companies, including AusBiotech members. AusBiotech will then hold the roundtables in March.
Biotech’s importance has been recognised by Government. An Australian Biotechnology 2030 Plan is being co-led between AusBiotech, the Department of Health, and the Department of Industry, Innovation, and Science; this decadal framework is a powerful long-term approach to healthcare and will facilitate the growth potential of the sector.
The results of both the survey and the focus groups help AusBiotech to build metrics on the significance of our industry and its perspectives, and to make strong statements about the magnitude of issues and trends. The collated results appear in a widely-used printed report that informs and gives valuable ballast to AusBiotech’s advocacy efforts. They will also help inform the Australian Biotechnology 2030 Plan.
The Survey is once again proudly supported by Grant Thornton, as part of its commitment to work constructively with the Australian biotechnology industry through its activities and support.
For further information, to signal interest in the roundtables, or to check if your company has participated, please contact Karen Parr, Communications Manager, on email@example.com.